Zapatero International Limited

Zapatero International Limited is a pharmaceutical importer and buyer based in Mauritius, specializing in the acquisition of finished pharmaceutical formulations. The company plays a pivotal role in the distribution of pharmaceutical products within the Mauritian market, ensuring the availability of essential medications to both public and private healthcare institutions. While specific details about its parent company are not publicly disclosed, Zapatero International Limited's operations are integral to the pharmaceutical supply chain in Mauritius.

The company operates from Freeport Zone 5, Mer Rouge, Port Louis, 11609, Republic of Mauritius. This strategic location facilitates efficient logistics and distribution across the island. While specific warehouse locations and logistics capabilities are not detailed, the company's significant import volume and the central location suggest a well-established distribution network capable of meeting the demands of the Mauritian pharmaceutical market.

Zapatero International Limited functions primarily as a pharmaceutical wholesaler in Mauritius. By importing a diverse range of finished pharmaceutical formulations, the company supplies these products to various stakeholders, including retail pharmacies, hospitals, and clinics. This role is crucial in ensuring the consistent availability of medications throughout the country, thereby supporting the healthcare system's efficacy.

The company's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.1 million USD from India, accounting for 100% of its pharmaceutical imports. This single-source dependency indicates a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities. The stability of this relationship is evidenced by 254 shipments from a single supplier, PLEASANT EXPORTS, suggesting a reliable and consistent supply chain. However, this concentration also presents a potential risk; any disruptions in India's pharmaceutical production or export policies could directly impact Zapatero International Limited's operations.

Zapatero International Limited's supply chain resilience is closely tied to its exclusive reliance on Indian suppliers, particularly PLEASANT EXPORTS. The absence of backup suppliers and the limited diversity in imported formulations may pose challenges in the event of supply chain disruptions. Additionally, the company's dependence on a single shipping route from India to Mauritius exposes it to potential logistical bottlenecks or geopolitical issues. Ensuring the regulatory compliance of key suppliers, such as PLEASANT EXPORTS, is essential to maintain uninterrupted supply and adhere to Mauritius's stringent pharmaceutical import regulations.

The concentrated sourcing pattern positions Zapatero International Limited to benefit from economies of scale and potentially favorable pricing from its Indian supplier. However, this strategy also makes the company vulnerable to supply chain disruptions originating from India. For Indian exporters, this presents an opportunity to strengthen their relationship with Zapatero International Limited by ensuring consistent quality and timely delivery, thereby solidifying their position as a preferred supplier.

The primary regulatory body overseeing pharmaceutical imports in Mauritius is the Pharmacy Board, operating under the Ministry of Health and Wellness. The governing legislation includes the Pharmacy Act 1983 and the Consumer Protection (Price and Supplies Control) Act of 1998. These laws establish the framework for the authorization, marketing, sale, and supply of pharmaceutical products in the country. The Pharmacy Act defines "pharmaceutical product" as a drug, medicine, preparation, poison, or therapeutic substance, and outlines the procedures for their registration and importation.

Importers of pharmaceutical products in Mauritius must obtain a clearance from the Registrar, as stipulated in Section 25A of the Pharmacy Act. This process involves submitting an application through the TradeNet system, accompanied by a pro forma invoice and other relevant documents. The Registrar reviews the application and, upon approval, grants clearance for the importation of the pharmaceutical products. Additionally, importers are required to ensure that the pharmaceutical products are registered with the Pharmacy Board and that the manufacturing facilities hold valid Good Manufacturing Practice (GMP) certifications recognized by the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

Imported pharmaceutical products must undergo batch testing to confirm their quality and safety. Stability requirements are enforced to ensure that products maintain their efficacy throughout their shelf life. Labeling must be in English or French, providing clear information on dosage, usage instructions, and storage conditions. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market. These measures are in line with the standards set by the Pharmacy Act and other relevant regulations.

Between 2024 and 2026, Mauritius implemented the Consumer Protection (Pharmaceutical Products) (Maximum Mark-Up) Regulations 2023. These regulations, effective from April 28, 2023, establish maximum mark-up percentages for pharmaceutical products, aiming to control pricing and ensure affordability for consumers. Importers and wholesalers, including Zapatero International Limited, must adhere to these regulations when pricing their products.

Zapatero International Limited's focus on advanced diabetes medications, particularly Semaglutide, reflects a strategic alignment with the growing demand for effective diabetes treatments in Mauritius. The substantial import value of Semaglutide ($775K) indicates a strong market presence and a commitment to providing high-quality therapeutic options. The inclusion of other antidiabetic agents like Empagliflozin, Canagliflozin, Linagliptin, and Saxagliptin in their portfolio suggests a comprehensive approach to addressing various patient needs within the diabetes care segment.

Zapatero International Limited's sourcing strategy is heavily reliant on Indian manufacturers, with PLEASANT EXPORTS being the sole supplier. This approach allows for streamlined procurement processes and potential cost advantages. The focus on finished pharmaceutical formulations, rather than raw Active Pharmaceutical Ingredients (APIs), indicates a preference for ready-to-market products that meet the regulatory standards of Mauritius.

By importing a specialized range of advanced diabetes medications, Zapatero International Limited positions itself as a key supplier in the Mauritian pharmaceutical market, particularly in the diabetes care segment. This strategic focus enables the company to cater to the needs of healthcare providers and patients seeking effective and reliable antidiabetic treatments.

The concentrated sourcing pattern of Zapatero International Limited presents an opportunity for new Indian suppliers to enter the market by offering complementary products or by ensuring consistent quality and supply reliability. Diversifying the supplier base could enhance the company's resilience and mitigate risks associated with single-source dependency.

Indian exporters aiming to supply pharmaceutical products to Zapatero International Limited must ensure that their manufacturing facilities hold valid GMP certifications recognized by WHO or PIC/S. Products must be registered with the Pharmacy Board of Mauritius, and all importation processes must comply with the regulations outlined in the Pharmacy Act and related legislation. Additionally, adherence to the Consumer Protection (Pharmaceutical Products) (Maximum Mark-Up) Regulations 2023 is mandatory.

Indian exporters should initiate contact with Zapatero International Limited by presenting their product portfolios, emphasizing compliance with international quality standards and the regulatory requirements of Mauritius. Participating in relevant trade fairs and industry events in Mauritius can facilitate relationship-building. Understanding the import licensing procedures and ensuring timely regulatory filings will be crucial. Establishing a clear timeline for product registration and importation, in line with the Pharmacy Act and other relevant regulations, will enhance the likelihood of successful market entry.